Actively Recruiting

Early Phase 1
Age: 25Years - 80Years
All Genders
NCT05997043

Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease

Led by Zhujiang Hospital · Updated on 2023-08-18

60

Participants Needed

1

Research Sites

148 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A randomized controlled trial is to be conducted to confirm the efficacy and safety of intramuscular injection of botulinum toxin in the treatment of Parkinson's bladder overactivity.

CONDITIONS

Official Title

Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease

Who Can Participate

Age: 25Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with idiopathic Parkinson's disease by an experienced neurologist using International Motor Disorder Association criteria
  • Have overactive bladder symptoms confirmed by a 3-day voiding diary and evaluated by OABSS score
  • Male or female aged between 25 and 80 years
  • Treated with dopaminergic drugs, with evaluation during wearing-off periods if applicable
  • Have a history of neurogenic detrusor overactivity lasting 3 months or more, with symptoms not fully controlled by anticholinergic drugs after adequate treatment
  • If taking anticholinergic drugs at baseline, must maintain a stable dose during the study; if not taking, cannot start during the study
  • Willing to begin intermittent catheterization if necessary
  • Provided informed consent for participation in the clinical trial
Not Eligible

You will not qualify if you...

  • Residual urine volume greater than 10 ml on bladder ultrasonography
  • Having glaucoma or myasthenia gravis, making botulinum toxin unsuitable
  • Require indwelling catheter or intermittent catheterization to empty the bladder
  • Previous treatment with botulinum toxin for any urinary disease
  • Known allergies to drugs or their ingredients
  • Using drugs that affect neuromuscular transmission
  • Receiving anticoagulant therapy
  • Infection at the injection site
  • Dementia with Parkinson's dementia scale score 73.5 or less at screening or having Parkinson's psychiatric disorder

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China, 510000

Actively Recruiting

Loading map...

Research Team

S

Shuzhen Zhu, Doctor

CONTACT

S

Shujuan Yang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here